TIMP-2 and IGFBP7 for the Prediction of the Cardiac Surgery Associated Acute Kidney Injury

Acute Kidney Injury Clinical Trial

Official title:

Novel Biomarkers (TIMP-2 and IGFBP7) of Tubular Renal Cell Damage for the Prediction of the Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) - A Feasibility Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02054546
• Other study ID #: 514/13
• Status: Completed
• Phase: N/A
• First received: February 3, 2014
• Last updated: February 26, 2015
• Start date: December 2013
• Est. completion date: December 2014

Study information

• Verified date: February 2015
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to analyze the new biomarkers (TIMP-2 and IGFBP-7) of tubular renal cell damage for the prediction of the Cardiac Surgery Associated acute kidney injury.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• planned cardiac surgery

Exclusion Criteria:

• renal dialysis

• minors

• emergency

• no cardiopulmonary bypass

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Kidney Injury

Locations

Country	Name	City	State
Switzerland	Universitätsspital Basel	Basel	Basel-Stadt

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	AKI Stadium 2-3 (KDIGO)		30 days	Yes
Primary	AKI-stadium 1 (KDIGO)		30 days	Yes
Secondary	all cause mortality		30 days	No